Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HUF)10,200.00
  • Today's Change-90.00 / -0.87%
  • Shares traded104.97k
  • 1 Year change+5.70%
  • Beta0.6266
Data delayed at least 15 minutes, as of Jul 11 2025 16:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.

  • Revenue in HUF (TTM)878.14bn
  • Net income in HUF239.17bn
  • Incorporated1923
  • Employees11.76k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
RICHTER:BUD since
announced
Transaction
value
Granata Bio IncDeal completed13 May 202513 May 2025Deal completed-3.77%--
Data delayed at least 15 minutes, as of Jul 11 2025 16:05 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Laurus Labs Ltd221.17bn14.27bn1.70tn6.17k118.999.5354.327.686.646.64102.8882.940.62681.313.039,005,935.004.008.886.4814.3155.3848.186.3811.880.67683.110.375213.7910.1814.42123.187.0223.60--
Siegfried Holding AG555.45bn68.49bn1.75tn3.89k24.434.0116.643.143.683.6829.9122.450.68222.363.02333,137.708.437.2110.348.8325.4224.1012.3510.201.8066.600.333413.141.829.2142.4628.1223.916.30
Axsome Therapeutics Inc147.70bn-95.11bn1.83tn683.00--100.81--12.42-5.77-5.778.951.080.75662.313.29632,733.50-48.72-59.62-73.77-80.3291.49---64.39-134.061.96-34.420.7784--42.53---20.05--75.71--
Beijing Tiantan Biological Products Corp292.15bn70.40bn1.85tn5.30k26.483.42--6.340.74240.74243.095.760.3950.840620.211,156,602.0013.0011.9318.4116.7951.5250.6932.9229.693.63--0.008616.2416.4412.9439.5820.4515.1923.56
Ono Pharmaceutical Co Ltd1.13tn116.03bn1.86tn4.29k15.140.968110.441.65106.52106.521,036.361,665.600.49242.403.79113,569,200.005.0710.785.8512.3769.6173.2310.3021.232.56142.590.156936.33-3.1410.73-60.89-3.47-18.6612.20
Richter Gedeon Vegyeszeti Gyar Nyrt878.14bn239.17bn1.90tn11.76k7.801.396.702.161,306.971,306.974,799.487,338.150.57581.313.8174,690,570.0015.6813.5517.3515.3568.7560.7927.2422.343.08--0.015640.476.5111.0550.6138.398.6251.82
Dottikon ES Holding AG165.29bn45.30bn1.91tn793.0041.564.4234.8311.547.647.6427.8871.790.3030.69524.88485,789.408.318.059.679.2567.3672.3727.4125.671.65--0.1159--18.0717.1330.9526.0623.40--
Rhythm Pharmaceuticals Inc46.78bn-59.47bn1.94tn283.00--290.55--41.53-2.78-2.782.222.570.42421.028.42483,614.80-52.29-52.46-70.40-61.2289.62---123.28-354.183.13--0.4018--68.06---43.26------
Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd3.55tn128.66bn1.97tn28.14k16.121.15--0.55321.661.6645.8423.200.93886.074.342,648,377.003.565.336.6710.9515.7718.073.795.281.24--0.323128.87-0.6922.92-30.09-2.32-14.016.32
TG Therapeutics Inc132.06bn13.38bn2.01tn352.00152.0024.72150.2015.240.2440.2442.401.500.75030.41273.031,143,154.007.60-42.9310.17-52.5587.43--10.13-142.453.042.250.5077--40.80364.5984.52---19.24--
Hikma Pharmaceuticals Plc1.08tn122.71bn2.02tn9.31k16.582.5610.651.871.191.1910.467.710.64321.823.63251,178.007.387.1911.1810.0045.8849.3511.4711.870.64567.580.360144.059.777.4588.95-5.884.7910.29
ALK-Abello A/S305.61bn50.17bn2.11tn2.74k45.507.6032.476.914.284.2826.0825.620.76251.266.442,073,375.0012.526.0115.297.6064.4561.9516.428.440.987557.350.12350.0014.7811.0867.70--50.82--
Data as of Jul 11 2025. Currency figures normalised to Richter Gedeon Vegyeszeti Gyar Nyrt's reporting currency: Hungarian Forint HUF

Institutional shareholders

19.38%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 May 20258.94m4.80%
The Vanguard Group, Inc.as of 02 Jul 20255.54m2.97%
Orbis Investment Management Ltd.as of 31 Dec 20243.87m2.08%
Seafarer Capital Partners LLCas of 31 Mar 20253.00m1.61%
Norges Bank Investment Managementas of 31 Dec 20242.79m1.50%
Templeton Asset Management Ltd.as of 30 May 20252.58m1.38%
Schroder Investment Management Ltd.as of 31 May 20252.52m1.35%
Artemis Investment Management LLPas of 28 Feb 20252.46m1.32%
Strategic Advisers LLCas of 31 May 20252.25m1.21%
BlackRock Fund Advisorsas of 03 Jul 20252.17m1.17%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.